Vaim

What Vaim does

Vaim (바임) is a South Korean medical aesthetic company that develops, manufactures, and commercializes collagen-generating injectable implants based on proprietary biocompatible and biodegradable polymer technology. The company combines PDLLA (Poly-D,L-Lactic Acid) micro-particles with hyaluronic acid (HA), structured through a patented porous reticular network (다공성 망상구조), to stimulate autologous collagen production for skin rejuvenation, wrinkle reduction, and volume restoration. Its core product family is the Juvelook line of Class 4 medical devices, marketed across particle size variants (Juvelook at 25µm, Juvelook Volume/Lenisna at 40µm, and the September 2025 launches Juvelook i at 20µm and Juvelook G at 65µm) to address a range of clinical indications.

Vaim operates a vertically integrated model spanning R&D, manufacturing, and field sales. Production runs across four facilities—Okcheon factory and Daejeon Factories 1, 2, and 3—with Factory 2 having tripled capacity in 2024 and Factory 3 opening in September 2024. Commercial operations rely on direct field sales through five Korean regional offices (Seoul, Daejeon, Gwangju, Daegu, Busan) serving approximately 1,800 dermatology and aesthetic clinics domestically, alongside an export network spanning 60 actively selling countries and supply contracts in 80 countries under the international brand name Lenisna for the volume variant. Marketing combines KOL engagement, clinical symposia (Jupiter Academic Symposium, KJEM), conference presence at IMCAS and AMWC, and direct-to-consumer activations including TV advertising with brand muse Kim Yoo-jung and pop-up experiences.

The business model is one-time product sale of medical devices to clinics and distributors, with revenue effectively recurring via clinic reorders. Revenue has doubled annually from the 2019 launch through 2024 (224% CAGR), reaching KRW 100 billion (~USD 75M) in 2022 per company commentary. The company has raised approximately KRW 40 billion cumulatively from Evermount Capital Management, including a January 2024 reinvestment of KRW 20 billion (~USD 15.3M) following a prior exit that yielded a 100% IRR, and is positioned for further institutional or public-market activity following a 2024 reverse stock split and a 2025 internal merger consolidating manufacturing and sales entities.

Name

Vaim

Legal name

VAIM CO., LTD.

Website

https://vaim.co.kr

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Vaim is a South Korean medical aesthetic company that develops and manufactures PDLLA-based collagen-generating injectable implants under the Juvelook brand, serving dermatology and aesthetic clinics in Korea and 60+ export countries through direct field sales and local distributors.

Ownership category

akta.pro rank

Product category

Medical Aesthetic Injectable Devices

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391), Toilet Preparation Manufacturing (325620)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Biocompatible polymer injectables
• Collagen stimulating fillers
• Medical aesthetic devices
• Dermal skin boosters
• PDLLA hyaluronic acid injectables

Headquarters

HQ city

Okchon

HQ country

South Korea

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Product Sales (Medical Devices): Revenue generated from the sale of Juvelook and related skin booster products to dermatology clinics and aesthetic medical institutions domestically and internationally.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Vaim develops and manufactures collagen-stimulating injectable medical devices (Class 4) based on PDLLA (Poly-D,L-Lactic Acid) microparticles combined with Hyaluronic Acid. Its flagship Juvelook line uses a patented porous reticular structure to induce natural collagen and elastin formation for skin rejuvenation, wrinkle improvement, and volume enhancement. Products are sold as Class 4 medical devices to dermatology and aesthetic clinics in Korea and exported globally to 60+ countries.

Product overview

Vaim is a medical aesthetic company specializing in collagen-generating injectable implants based on PDLLA (Poly-D,L-Lactic Acid) biocompatible polymer technology combined with hyaluronic acid (HA). The product portfolio centers on the Juvelook line, which includes the original Juvelook (25um particle size for general skin rejuvenation), Juvelook Volume/Lenisna (40um for volumization), Juvelook i (20um for fine wrinkles and thin skin), and Juvelook G (65um for deep wrinkles and broad areas). All products share the same core PDLLA + HA composition but differ in particle size and concentration to target different treatment areas and clinical outcomes. The company also maintains manufacturing operations for these Class 4 medical devices.

Differentiator

Problem solved

Functional benefit

Brands

• Juvelook (쥬베룩): Collagen-generating skin booster injectable product based on PDLLA (Poly D,L-Lactic Acid) micro-particles combined with hyaluronic acid (HA). A Class 4 medical device with the company's patented porous reticular structure. Available in multiple formulations: Juvelook (42.5mg PLA + 7.5mg HA per vial), Juvelook Volume (170mg PLA + 30mg HA per vial), Juvelook i, and Juvelook G.
• Juvelook Volume (쥬베룩 볼륨)
• Lenisna (레니스나)
• Juvelook i
• Juvelook G

Products and services

• Juvelook (쥬베룩) Collagen-generating skin booster injectable using PDLLA (Poly-D,L-Lactic Acid) 42.5mg combined with hyaluronic acid (HA) 7.5mg per vial. Designed for skin rejuvenation, wrinkle improvement, and volume enhancement through autologous collagen stimulation. Class 4 medical device.
• Juvelook Volume (쥬베룩 볼륨) Volume-focused variant of Juvelook with larger PDLLA particle size (40μm compared to 25μm for original Juvelook). Designed for deeper wrinkle improvement and broader area treatment with stronger volumization effects. Contains same PDLLA and HA composition at higher concentration (170mg PLA + 30mg HA per vial).
• Lenisna (레니스나) International export brand name for Juvelook Volume. Soft tissue injectable implant using PLA (Poly-D,L-Lactic Acid) 170mg combined with HA (Sodium Hyaluronate) 30mg per vial. Classified as disposable medical device (PLA filler) for temporary improvement of facial wrinkles in adults.
• Juvelook i (쥬베룩 i) Variant of Juvelook with smaller PDLLA particle size (20μm) compared to original Juvelook (25μm). Designed for thin skin areas and fine wrinkle improvement applications. Same core PDLLA + HA composition with differentiated particle size for targeted treatment.
• Juvelook G (쥬베룩 G) Variant of Juvelook with larger PDLLA particle size (65μm) compared to Juvelook Volume (40μm). Designed for broader areas and deeper wrinkle improvement with enhanced volumization capability. Same core PDLLA + HA composition with larger particle size for targeted treatment.

Quantifiable outcome

• 224% revenue CAGR from 2019 to 2024 (doubling every year)
• +4 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Galderma: Global aesthetics leader with Sculptra (poly-L-lactic acid / PLLA biostimulator), the most direct competitor to Vaim's Juvelook PDLLA+HA injectable. Also offers Restylane HA filler portfolio, targeting the same dermatology clinic channel.
• Merz Aesthetics: Global aesthetics company behind Radiesse (calcium hydroxylapatite biostimulator) and Belotero HA fillers. Competes with Vaim in the collagen stimulation category across dermatology clinics worldwide.
• Humedix (Daewoong affiliate): Korean aesthetics company developing HA-based cross-linked dermal fillers (e.g., Dermalax line). Direct competitor in Korean and international medical aesthetic injectable markets with similar Class 4 medical device profile.
• Sinclair Pharma (now part of Galderma): Developer of Ellansé, a polycaprolactone (PCL) collagen biostimulator competing directly with Juvelook in the same regenerative injectable category, with established European and Asian commercial presence.
• Croma-Pharma: Austrian aesthetics company producing HA-based dermal fillers (Princess line) and biostimulator products. Competes in the same dermatology/aesthetic clinic channel with comparable injectable aesthetic offerings.
• Teoxane: Swiss aesthetics company specializing in HA-based dermal fillers (Teosyal line) with global distribution. Competes in the regenerative/cosmetic injectable space with similar dermatologist-focused commercial model.

Broad incumbents

• AbbVie (Allergan Aesthetics): Owner of the Juvederm HA filler family and Botox, dominating the medical aesthetics market. While not a direct PDLLA competitor, it represents the broad incumbent that Vaim's products must displace in clinic formularies.

Regional players

• Medytox: South Korean biopharmaceutical company known for botulinum toxin (Meditoxin/Nabota) and dermal fillers. Direct Korean regional competitor in the same domestic aesthetic injectable market and international export channels.
• Daewoong Pharmaceutical: Major Korean pharmaceutical company with aesthetic injectable portfolio (Nabota botulinum toxin, dermal fillers). Competes in domestic Korean clinics and exports to similar international markets as Vaim.
• LG Chem (LG Household & Health Care): Korean conglomerate's life sciences division producing Yvoire HA dermal fillers. Competes primarily in Asian markets with comparable injectable aesthetic products targeting dermatology clinics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vaim-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaim